Improving immune therapy for small cell lung cancer
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
['FUNDING_R01'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-11064879
This study is looking at a new way to make treatments for small cell lung cancer work better by using special drugs to target a process that helps the cancer grow, which could help your immune system fight the cancer more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11064879 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing immune checkpoint blockade therapy for small cell lung cancer (SCLC) by targeting the replication stress response (RSR). The approach involves using small molecule inhibitors to disrupt RSR, which is overactive in SCLC, thereby increasing the effectiveness of immune responses against the cancer. The study aims to understand how inhibiting RSR can boost the expression of PD-L1, a protein that helps tumors evade the immune system, and activate innate immune pathways to improve treatment outcomes. By investigating these mechanisms, the research seeks to develop new immunotherapy strategies that can be applied in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who may benefit from enhanced immune therapies.
Not a fit: Patients with other types of lung cancer or those who do not have small cell lung cancer may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with small cell lung cancer.
How similar studies have performed: Previous research has shown promising results in targeting replication stress to improve cancer therapies, indicating potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SEN, TRIPARNA — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Study coordinator: SEN, TRIPARNA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer research